NASDAQ:TCRX

TScan Therapeutics (TCRX) Stock Forecast, Price & News

$2.65

0.00 (0.00%)

(As of 09/22/2023 ET)

Compare

Today's Range: $2.52
▼
$2.70
50-Day Range: $2.04
▼
$2.94
52-Week Range: $1.45
▼
$6.03

Volume: 20,867 shs
Average Volume: 189,985 shs
Market Capitalization: $126.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.50

TScan Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 334.0% Upside
$11.50 Price Target
Short Interest: Healthy
0.86% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.80) to ($1.77) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

447th out of 967 stocks

Biological Products, Except Diagnostic Industry

64th out of 159 stocks

3.5

Analyst's Opinion

Consensus Rating
TScan Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.50, TScan Therapeutics has a forecasted upside of 334.0% from its current price of $2.65.
Amount of Analyst Coverage
TScan Therapeutics has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.86% of the float of TScan Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
TScan Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in TScan Therapeutics has recently decreased by 4.97%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
TScan Therapeutics does not currently pay a dividend.
Dividend Growth
TScan Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TCRX.

1.1

News and Social Media Coverage

Search Interest
2 people have searched for TCRX on MarketBeat in the last 30 days.
MarketBeat Follows
2 people have added TScan Therapeutics to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TScan Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.27% of the stock of TScan Therapeutics is held by insiders.
Percentage Held by Institutions
67.73% of the stock of TScan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for TScan Therapeutics are expected to grow in the coming year, from ($1.80) to ($1.77) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TScan Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TScan Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TScan Therapeutics has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About TScan Therapeutics (NASDAQ:TCRX) Stock

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors. The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors. In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

TCRX Price History

30 days | 90 days | 365 days | Advanced Chart

TCRX Stock News Headlines

September 12, 2023 | finance.yahoo.com

Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

August 29, 2023 | finance.yahoo.com

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME

September 23, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

August 16, 2023 | finance.yahoo.com

TScan Therapeutics, Inc. (TCRX) Upgraded to Buy: Here's What You Should Know

August 11, 2023 | markets.businessinsider.com

Barclays Remains a Buy on TScan Therapeutics (TCRX)

August 10, 2023 | finance.yahoo.com

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

July 21, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Legend Biotech (LEGN), Gossamer Bio (GOSS) and TScan Therapeutics (TCRX)

June 29, 2023 | finanznachrichten.de

TScan Therapeutics, Inc.: TScan Therapeutics Announces Transition of Chief Financial Officer

September 23, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

June 29, 2023 | markets.businessinsider.com

TScan Therapeutics CFO Brian Silver To Step Down

June 29, 2023 | finance.yahoo.com

TScan Therapeutics Announces Transition of Chief Financial Officer

June 22, 2023 | msn.com

Wedbush Initiates Coverage of Tscan Therapeutics (TCRX) with Outperform Recommendation

June 15, 2023 | finance.yahoo.com

Favourable Signals For TScan Therapeutics: Numerous Insiders Acquired Stock

June 15, 2023 | finance.yahoo.com

Favourable Signals For TScan Therapeutics: Numerous Insiders Acquired Stock \

June 7, 2023 | benzinga.com

TScan Therapeutics Insider Trades Send a Signal

June 6, 2023 | finance.yahoo.com

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors

June 1, 2023 | finance.yahoo.com

TScan Therapeutics Announces Closing of Public Offering

June 1, 2023 | finance.yahoo.com

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting

June 1, 2023 | finance.yahoo.com

TScan Therapeutics to Participate in the Jefferies Healthcare Conference

May 26, 2023 | markets.businessinsider.com

TScan Announces Pricing Of Underwritten Public Offering - Quick Facts

May 26, 2023 | msn.com

TScan Therapeutics stock slides on pricing $140M securities offering

May 26, 2023 | finance.yahoo.com

TScan Therapeutics Announces Pricing of $140 Million Public Offering

May 25, 2023 | msn.com

TScan Therapeutics plans for stock and warrants offering

May 25, 2023 | finance.yahoo.com

TScan Therapeutics Announces Launch of Proposed Public Offering

May 24, 2023 | msn.com

TScan Therapeutics names Gavin MacBeath permanent CEO

May 24, 2023 | finance.yahoo.com

TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors

May 17, 2023 | finance.yahoo.com

TScan Therapeutics Shares Fall After Preliminary Data Highlight In Leukemia Patients

See More Headlines

Receive TCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRX Company Calendar

Last Earnings: 8/10/2023
Today: 9/23/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TCRX
CUSIP: N/A
CIK: 1783328
Web: www.tscan.com
Phone: 857-399-9500
Fax: N/A
Employees: 135
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.50
High Stock Price Forecast: $15.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +334.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-66,220,000.00
Net Margins: -497.11%
Pretax Margin: -497.11%
Return on Equity: -67.32%
Return on Assets: -38.16%

Debt

Debt-to-Equity Ratio: 0.16
Current Ratio: 6.90
Quick Ratio: 6.90

Sales & Book Value

Annual Sales: $13.53 million
Price / Sales: 9.37
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.10 per share
Price / Book: 0.65

Miscellaneous

Outstanding Shares: 47,820,000
Free Float: 43,864,000
Market Cap: $126.72 million
Optionable: Not Optionable
Beta: 0.34

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Gavin MacBeath Ph.D. (Age 53)
CEO, Director & Interim Principal Financial Officer
Comp: $650.17k

Dr. Stephen J. Elledge Ph.D.
Co-Founder & Chairman of Scientific Advisory Board

Mr. Tomasz Kula Ph.D.
Co-Founder & Member of Advisory Board

Mr. Leiden Dworak
Principal Accounting Officer

Mr. Ray Lockard
Sr. VP of Technical Operations & Quality

Ms. Heather Savelle
VP of Investor Relations

Dr. Zoran Zdraveski J.D. (Age 53)
Ph.D., Chief Legal Officer & Company Sec.

Ms. Ann Hargraves
Sr. VP of HR

Dr. Shrikanta Chattopadhyay M.D.
Sr. VP of Medical & Translational Medicine

Dr. Debora Barton M.D. (Age 47)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TCRX Stock - Frequently Asked Questions

Should I buy or sell TScan Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TScan Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TCRX shares.
View TCRX analyst ratings or view top-rated stocks.
What is TScan Therapeutics' stock price forecast for 2023?: 2 equities research analysts have issued twelve-month target prices for TScan Therapeutics' stock. Their TCRX share price forecasts range from $8.00 to $15.00. On average, they expect the company's stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 334.0% from the stock's current price.
View analysts price targets for TCRX or view top-rated stocks among Wall Street analysts.
How have TCRX shares performed in 2023?: TScan Therapeutics' stock was trading at $1.55 at the beginning of 2023. Since then, TCRX stock has increased by 71.0% and is now trading at $2.65.
View the best growth stocks for 2023 here.
When is TScan Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our TCRX earnings forecast.
How were TScan Therapeutics' earnings last quarter?: TScan Therapeutics, Inc. (NASDAQ:TCRX) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.76) by $0.25. The business had revenue of $3.15 million for the quarter, compared to analyst estimates of $3.75 million. TScan Therapeutics had a negative net margin of 497.11% and a negative trailing twelve-month return on equity of 67.32%.
What ETF holds TScan Therapeutics' stock ?: Simplify Propel Opportunities ETF holds 1,046,916 shares of TCRX stock, representing 2.20% of its portfolio.

When did TScan Therapeutics IPO?: (TCRX) raised $100 million in an initial public offering on Friday, July 16th 2021. The company issued 6,250,000 shares at a price of $15.00-$17.00 per share.
What is TScan Therapeutics' stock symbol?: TScan Therapeutics trades on the NASDAQ under the ticker symbol "TCRX."
Who are TScan Therapeutics' major shareholders?: TScan Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BVF Inc. IL (12.34%), BlackRock Inc. (5.21%), Monashee Investment Management LLC (1.65%), Renaissance Technologies LLC (0.61%), Geode Capital Management LLC (0.48%) and Stifel Financial Corp (0.41%). Insiders that own company stock include Brian M Silver, David P Southwell, Gavin Macbeath, Lynx1 Capital Management Lp, Timothy J Barberich and Zoran Zdraveski.
View institutional ownership trends.
How do I buy shares of TScan Therapeutics?: Shares of TCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is TScan Therapeutics' stock price today?: One share of TCRX stock can currently be purchased for approximately $2.65.
How much money does TScan Therapeutics make?: TScan Therapeutics (NASDAQ:TCRX) has a market capitalization of $126.72 million and generates $13.53 million in revenue each year. The company earns $-66,220,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis.
How many employees does TScan Therapeutics have?: The company employs 135 workers across the globe.
How can I contact TScan Therapeutics?: TScan Therapeutics' mailing address is 830 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.tscan.com. The company can be reached via phone at 857-399-9500 or via email at tscan@argotpartners.com.

This page (NASDAQ:TCRX) was last updated on 9/23/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

TScan Therapeutics (TCRX) Stock Forecast, Price & News

TScan Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About TScan Therapeutics (NASDAQ:TCRX) Stock

TCRX Price History

TCRX Stock News Headlines

TCRX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

TCRX Stock - Frequently Asked Questions

Overall MarketRank^™